1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
Get alerted about grants like this
Save a search for “National Institutes of Health” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: Small businesses. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $150K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is July 8, 2013. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Purpose. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, enhance and validate translational tools to facilitate rigorous study of complementary and alternative medicine (CAM) approaches that are in wide use by the public. Recent data from the National Health Interview Survey [http://www.cdc.gov/nchs/nhis.htm] establish that Americans are utilizing CAM approaches to promote health and well-being, to treat or prevent disease, and for symptom relief. CAM approaches being widely used include massage and manipulative therapies, meditation, yoga, and acupuncture. Health conditions, particularly chronic pain, back pain and musculoskeletal pain, are the most commonly cited reasons for their use. This FOA focuses on encouraging the development of improved tools to study safety, efficacy, and clinical effectiveness of widely used CAM approaches, such as: mind-body interventions, manual therapies, yoga, and acupuncture. This FOA is not focused on tools for the study of natural products, such as herbal therapies. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, RFA-AT-09-002, which solicits applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 5 projects awarded as a result of this announcement is $1.25 million for fiscal year 2010. Future year amounts will depend on annual appropriations. Funding Opportunity Number: RFA-AT-09-004. Assistance Listing: 93.213. Funding Instrument: G. Category: HL. Award Amount: $1.3M total program funding.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
-This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the modification or development of new screening technologies that are better able to consistently detect mild hearing loss (i.e., less than 40 dB Hearing Level or 40 dB HL) in one or both ears in infants and young children without significantly increasing the number of false positives (i.e., those who fail the screen but do not have hearing loss). -The Early Hearing Detection and Intervention (EHDI) program within the National Center for Birth Defects and Developmental Disabilities (NCBDDD) of the Centers for Disease Control and Prevention (CDC) and the National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, are working to ensure infants and children with mild forms of hearing loss are identified as soon as possible. Part of this effort involves having screening technology available that can reliably detect these hearing losses. -This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-06-547, that solicits applications under the Small Business Technology Transfer (STTR [R41/R42]) grant mechanisms. Note,that CDC does not accept STTR applications so is participating only in PA-06-546. Funding Opportunity Number: PA-06-546. Assistance Listing: 93.173,93.283. Funding Instrument: G. Category: HL.